- Research Letter
- Open Access
Early identification of patients at high risk of group A streptococcus-associated necrotizing skin and soft tissue infections: a retrospective cohort study
Critical Care volume 23, Article number: 417 (2019)
Necrotizing soft tissue infections (NSTIs) are a heterogeneous group of devastating diseases involving a wide variety of microorganisms and affecting different body areas. The need for individualized treatment strategies has been recently put forward in a prospective cohort study of 402 patients in which group A streptococcus (GAS) infections were associated with more frequent septic shock . Early identification of patients with GAS-related NSTIs could prompt initiation of targeted interventions, including clindamycin and intravenous immunoglobulins (IVIg). These drugs might be associated with beneficial anti-toxinic properties, but the level of evidence supporting them remains low (clindamycin) or highly controversial (IVIg) [2, 3]. The only randomized clinical trial evaluating the effect of IVIg specifically in patients with NSTI could not demonstrate a benefit on a composite outcome of death and quality-of-life evaluation at 6 months . As previously commented , only 15% (n = 13/87) of included patients eventually had a microbiologically proven GAS NSTI. This was a major limitation and early identification of patients with a high probability of GAS-associated NSTIs would thus be crucial for further studies evaluating similar interventions.
A secondary analysis of a retrospective cohort including 224 patients admitted to our center for NSTI between 2006 and 2017 was conducted . In accordance with the most recent guidelines, only patients with surgically confirmed NSTI were included (i.e., macroscopic appearance of tissues during operation as swollen, dull gray with a thin, brownish exudate with or without necrosis). Admission characteristics and microbiological documentation based on surgical samples, blood cultures, or subcutaneous puncture were recorded. We compared patients with a documented GAS infection to other patients regarding admission characteristics. A multivariable logistic regression model was used to identify admission characteristics associated with a subsequent GAS documentation.
Among 224 patients, 60 (27%) had a GAS infection, which was monomicrobial in 39 (17%) cases. Overall, 134 (59.8%) patients were admitted to the intensive care unit during their stay, of whom 113 during the first 24 h. Ninety-one (41%) patients presented with shock (i.e., required vasopressors), and 89 (40%) required mechanical ventilation. Sixty days after admission, 51 (23%) patients had died, including 10 (17%) with GAS, and 41 (25%) with non-GAS infections (p = 0.255, Mann-Whitney test). Admission characteristics associated with GAS infections by univariable analysis were non-steroidal anti-inflammatory drug treatment before admission and leukocytosis as a continuous variable. Those inversely associated with GAS infections were immunodeficiency, the nosocomial onset of infection, and an abdominoperineal location (Table 1). After multivariable analysis, only immunodeficiency (adjusted odds ratio (aOR) = 0.29 [0.10–0.74], p = 0.015) and an abdominoperineal location (aOR = 0.06 [0.00–0.30], p = 0.007) remained associated with the absence of GAS infection (Table 1). A sensitivity analysis using “monomicrobial GAS NSTI” as the dependent variable yielded similar results, except for younger age that remained in the model after adjustment (data not shown). Immunodeficiency (n = 58) and an abdominoperineal location (n = 38) had respective positive predictive values for the absence of a GAS infection (both mono- or polymicrobial) of 90% [79–96] and 97% [86–100] (Fig. 1).
In conclusion, we retrospectively identified two simple and available upon admission clinical predictors of GAS documentation among a large cohort of surgically proven NSTIs. Our results show that NSTI patients with pre-existing immunodeficiency or an abdominal infection have a low probability of GAS infection and might thus not be suitable for inclusion in a trial assessing the effect of GAS-specific interventions. Such findings need to be assessed in a validation cohort in order to reinforce their generalizability. Improving identification upon admission of a subgroup of patients with a higher prevalence of GAS infection might help design future prospective trials aimed at assessing personalized treatment strategies .
Availability of data and materials
The dataset used during the current study is available from the corresponding author upon reasonable request.
Group A streptococcus
Necrotizing soft tissue infection
Positive predictive value
Negative predictive value
INFECT study group, Madsen MB, Skrede S, Perner A, Arnell P, Nekludov M, et al. Patient’s characteristics and outcomes in necrotising soft-tissue infections: results from a Scandinavian, multicentre, prospective cohort study. Intensive Care Med. 2019;45(9):1241–51.
Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37(3):333–40.
Carapetis JR, Jacoby P, Carville K, Ang S-JJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;59(3):358–65.
Madsen MB, Hjortrup PB, Hansen MB, Lange T, Norrby-Teglund A, Hyldegaard O, et al. Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. Intensive Care Med. 2017;43(11):1585–93.
de Prost N, Lipman J, Mimoz O. Therapeutic targets in necrotizing soft tissue infections. Intensive Care Med. 2017;43(11):1717–9.
Urbina T, Hua C, Sbidian E, Bosc R, Tomberli F, Lepeule R, et al. Impact of a multidisciplinary care bundle for necrotizing skin and soft tissue infections: a retrospective cohort study. Ann Intensive Care. 2019;9(1):123.
The members of the Henri Mondor Hospital Necrotizing Fasciitis Group are Romain BOSC, Cécile CHAMPY, Olivier CHOSIDOW, Nicolas de PROST, Nicola DE ANGELIS, Jean-Winoc DECOUSSER, Camille GOMART, Jean-Michel GRACIES, Barbara HERSANT, Camille HUA, Raphaël LEPEULE, Alain LUCIANI, Lionel NAKAD, Alain RAHMOUNI†, Emilie SBIDIAN, Françoise TOMBERLI, Tomas URBINA, and Paul-Louis WOERTHER.
This work did not receive any funding.
Ethics approval and consent to participate
The study was approved by the Comité de Protection des Personnes Ile-de-France V on March 8, 2018 (reference #16165). Patients received information during hospital stay that data abstracted from their medical charts could be used for research purposes.
Consent for publication
PLW declares having received lecture fees and conference invitations from MSD.
All other authors declare no competing interest for this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Urbina, T., Hua, C., Woerther, PL. et al. Early identification of patients at high risk of group A streptococcus-associated necrotizing skin and soft tissue infections: a retrospective cohort study. Crit Care 23, 417 (2019). https://doi.org/10.1186/s13054-019-2708-y
- Necrotizing soft tissue infection
- Group A streptococcus
- Intravenous immunoglobulins